MannKind Corp (MNKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
MannKind Corp (MannKind) is a bio-pharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products to treat diseases such as diabetes and cancer. The company’s product portfolio comprises one marketed product Afrezza, a rapid-acting inhaled insulin aimed to enhance glycemic control and is indicated for the treatment of diabetes. Afrezza is the only approved inhaled insulin for the treatment of diabetes in the US. The company develops its products based on its proprietary formulation technology, Technosphere. MannKind’s clinical research and development operations are conducted in Paramus, New Jersey and its manufacturing operations are carried out in Danbury, Connecticut. MannKind is headquartered in California, the US.
MannKind Corp Key Recent Developments
Jan 09, 2017: MannKind Receives $30.6 Million From Sanofi
Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks
Jan 03, 2017: MannKind Receives $1 Million Milestone From RLS
Nov 09, 2016: MannKind Reports 2016 Third Quarter Financial Results
Aug 08, 2016: MannKind Reports 2016 Second Quarter Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
MannKind Corp - Key Facts 6
MannKind Corp - Key Employees 7
MannKind Corp - Key Employee Biographies 8
MannKind Corp - Major Products and Services 9
MannKind Corp - Pharmaceutical Pipeline Products Data 10
MannKind Corp, Pipeline Products by Therapy Area 10
MannKind Corp, Pipeline Products by Development Phase 11
MannKind Corp - History 12
MannKind Corp - Company Statement 14
MannKind Corp - Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
MannKind Corp - Business Description 16
MannKind Corp - Corporate Strategy 17
MannKind Corp - SWOT Analysis 18
SWOT Analysis - Overview 18
MannKind Corp - Strengths 18
MannKind Corp - Weaknesses 19
MannKind Corp - Opportunities 20
MannKind Corp - Threats 21
MannKind Corp - Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios - Capital Market Ratios 23
Financial Ratios - Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios - Interim Ratios 27
Financial Ratios - Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30
MannKind Corp, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Jan 09, 2017: MannKind Receives $30.6 Million From Sanofi 32
Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 33
Jan 03, 2017: MannKind Receives $1 Million Milestone From RLS 34
Nov 09, 2016: MannKind Reports 2016 Third Quarter Financial Results 35
Aug 08, 2016: MannKind Reports 2016 Second Quarter Financial Results 37
May 09, 2016: MannKind Reports 2016 First Quarter Financial Results 38
Apr 19, 2016: MannKind Expands Commercial Capabilities With Two New Hires 39
Mar 14, 2016: MannKind Reports 2015 Fourth Quarter and Full Year Financial Results 40
Mar 14, 2016: MannKind Announces Appointment of Michael Castagna as Chief Commercial Officer 41
Feb 19, 2016: Alfred Mann Steps Down as Executive Chairman of Mannkind 42
Section 6 – Appendix 43
Methodology 43
Ratio Definitions 43
About GlobalData 47
Contact Us 47
Disclaimer 47
List of Tables
MannKind Corp, Key Facts 6
MannKind Corp, Key Employees 7
MannKind Corp, Key Employee Biographies 8
MannKind Corp, Major Products and Services 9
MannKind Corp, Number of Pipeline Products by Therapy Area 10
MannKind Corp, Number of Pipeline Products by Development Stage 11
MannKind Corp, History 12
MannKind Corp, Other Locations 15
MannKind Corp, Key Competitors 22
MannKind Corp, Ratios based on current share price 23
MannKind Corp, Annual Ratios 24
MannKind Corp (Cont...1), Annual Ratios 25
MannKind Corp, Interim Ratios 27
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30
MannKind Corp, Recent Deals Summary 31
Currency Codes 43
Capital Market Ratios 43
Equity Ratios 44
Profitability Ratios 44
Cost Ratios 45
Liquidity Ratios 45
Leverage Ratios 45
Efficiency Ratios 46
List of Figures
MannKind Corp, Pipeline Products by Therapy Area 10
MannKind Corp, Pipeline Products by Development Phase 11
MannKind Corp, Performance Chart (2011 - 2015) 26
MannKind Corp, Ratio Charts 28
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29
MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 30